CLINICAL TRIALS PROFILE FOR ARICEPT

All Clinical Trials for ARICEPT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000173 ↗	Memory Impairment Study (Mild Cognitive Impairment Study)	Completed	Alzheimer's Disease Cooperative Study (ADCS)	Phase 3	1999-03-01	The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00000173 ↗	Memory Impairment Study (Mild Cognitive Impairment Study)	Completed	National Institute on Aging (NIA)	Phase 3	1999-03-01	The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. An NIA-funded study recently confirmed that MCI is different from both dementia and normal age-related changes in memory. Accurate and early evaluation and treatment of MCI individuals might prevent further cognitive decline, including development of Alzheimer's disease (AD). The Memory Impairment Study is the first such AD prevention clinical trial carried out by NIH, and will be conducted at 65-80 medical research institutions located in the United States and Canada. This study will test the usefulness of two drugs to slow or stop the conversion from MCI to AD. The trial will evaluate placebo, vitamin E, and donepezil, an investigational agent approved by the Food and Drug Administration for another use. Vitamin E (alpha-tocopherol) is thought to have antioxidant properties, and was shown in a 1997 study to delay important dementia milestones, such as patients' institutionalization or progression to severe dementia, by about seven months.
NCT00004807 ↗	Study of the Pathogenesis of Rett Syndrome	Completed	Johns Hopkins University	N/A	1995-01-01	OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00004807 ↗	Study of the Pathogenesis of Rett Syndrome	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	1995-01-01	OBJECTIVES: I. Extend current knowledge of the phenotype and natural history of Rett syndrome (RS). II. Continue the search for a cytogenetic and/or DNA marker. III. Study the effects of cholinergic drugs based on preliminary evidence for reduced levels of brain acetylcholine, while continuing supportive care to modify seizures, respiratory abnormalities, and motor disturbances, and improve nutrition, behavior, and learning. IV. Identify targets for future therapeutic interventions, e.g., growth factors, to influence neurologic recovery.
NCT00018278 ↗	Electrophysiologic Measures of Treatment Response in Alzheimer Disease	Completed	US Department of Veterans Affairs	Phase 4	1998-10-01	The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.
NCT00018278 ↗	Electrophysiologic Measures of Treatment Response in Alzheimer Disease	Completed	VA Office of Research and Development	Phase 4	1998-10-01	The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Clinical Trial Conditions for ARICEPT

Condition Name

Condition Name for ARICEPT
Intervention	Trials
Alzheimer's Disease	36
Alzheimer Disease	22
Healthy	14
Dementia	10

Condition MeSH

Condition MeSH for ARICEPT
Intervention	Trials
Alzheimer Disease	67
Dementia	25
Cognitive Dysfunction	19
Cognition Disorders	15

Clinical Trial Locations for ARICEPT

Trials by Country

Trials by Country for ARICEPT
Location	Trials
United States	341
Canada	46
Japan	28
Korea, Republic of	25
United Kingdom	23

Trials by US State

Trials by US State for ARICEPT
Location	Trials
California	25
Florida	21
Texas	21
New York	18
Arizona	17

Clinical Trial Progress for ARICEPT

Clinical Trial Phase

Clinical Trial Phase for ARICEPT
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	32
Phase 3	21

Clinical Trial Status

Clinical Trial Status for ARICEPT
Clinical Trial Phase	Trials
Completed	112
Terminated	16
Unknown status	7

Clinical Trial Sponsors for ARICEPT

Sponsor Name

Sponsor Name for ARICEPT
Sponsor	Trials
Pfizer	18
Eisai Inc.	15
National Institute of Mental Health (NIMH)	9

Sponsor Type

Sponsor Type for ARICEPT
Sponsor	Trials
Industry	118
Other	93
NIH	25

ARICEPT Market Analysis and Financial Projection

Last updated: April 28, 2026

What Is the Current Clinical and Market Status of Aricept (Donepezil)?

Aricept is an approved symptomatic treatment for Alzheimer’s disease (AD). It is not in active late-stage global pivotal trials for new indications based on the latest broadly reported public evidence, and commercial performance is driven by (1) ongoing prescription demand in established markets, (2) competitive dynamics vs other AD symptomatic therapies and disease-modifying approaches, and (3) generic erosion in markets where patent protection has expired.

---

What Is Aricept and How Is It Used Clinically?

Active ingredient: donepezil hydrochloride
Clinical role: acetylcholinesterase inhibitor for symptomatic treatment of mild, moderate, and severe Alzheimer’s disease dementia.
Core endpoints historically used in approvals: cognitive and global function measures (e.g., ADAS-Cog and clinician/caregiver global assessment scales), with response assessed over weeks to months.

Regulatory positioning: Aricept is a legacy standard-of-care symptomatic drug, not a disease-modifying therapy. That matters for trial design and endpoints: ongoing clinical evidence tends to be supportive (formulations, dosing strategies, real-world evidence) rather than curative claims.

---

Which Clinical Trials Should Be Considered “Active” for Aricept?

Aricept’s clinical development status is best understood as post-approval lifecycle activity rather than new registrational programs. Publicly indexed trial activity for donepezil generally clusters into:

1. Formulation and dosing optimization (e.g., donepezil tablets vs orally disintegrating formulations; switch/maintenance studies)
2. Comparative effectiveness and real-world evidence (observational cohorts, pragmatic trials)
3. Combination studies (donepezil plus another symptomatic agent or supportive care)
4. Rare or exploratory indications (less common, often small and not registrational)

A definitive “active late-stage global pivotal” update for Aricept is not supported by the typical current registrational pattern for legacy generics in Alzheimer’s. The dominant signal in the market comes from continued prescribing plus generic competition, not from ongoing Phase 3 readouts that would shift the label.

---

What Does the Market Landscape Look Like?

Competitive context

Aricept competes in Alzheimer’s symptom management with:

• Other acetylcholinesterase inhibitors (e.g., rivastigmine, galantamine)
• Memantine (NMDA antagonist) and combination regimens used clinically in moderate-to-severe disease
• Disease-modifying therapies (where available) that can reduce the addressable segment for purely symptomatic approaches over time

Generic pressure

Donepezil is widely generic in most major markets. Generic availability compresses pricing and shifts share toward lower-cost supply chains, with brand value primarily maintained through:

• entrenched prescriber familiarity
• managed-care contracting
• patient tolerability and switching costs
• distribution strength and pharmacy benefit dynamics

Demand drivers

1. Alzheimer’s disease prevalence growth
2. High persistence in symptomatic therapy because cognitive stabilization is clinically meaningful even without disease modification
3. Treatment guidelines that still list acetylcholinesterase inhibitors as core symptomatic options
4. Formulary inclusion and step-therapy policies (plan-specific)

---

How to Think About Market Projection for Aricept

Base case market mechanics

Aricept’s future commercial trajectory typically follows four forces:

1. Diagnosis and treatment rate growth (expanding treated population)
2. Pricing compression from generic competition
3. Substitution pressures from other symptomatic therapies and combination strategies
4. Label and payer behavior as disease-modifying therapies expand in eligible patients

Projection logic

A credible projection for Aricept in investment terms is less about launching new indications and more about estimating:

• Treated population growth for AD dementia
• Share of prescriptions relative to competing cholinesterase inhibitors
• Net price decline from generic mix and rebate pressure
• Potential label or guideline shifts that favor specific symptomatic regimens

Since Aricept is not in a new registrational expansion pattern, projections generally show stabilization or slow decline in revenue in mature markets, with variation tied to how fast bios and disease-modifying adoption changes symptomatic-only utilization.

---

Clinical Trial Update: Where Aricept’s Evidence Is Most Likely to Matter Now

Even without a new Phase 3 headline, Aricept’s “clinical update” can still be material for market behavior if it affects:

• Switching rules in formularies (e.g., tolerability, adherence, once-daily dosing preference)
• Real-world persistence vs alternatives
• Combination use patterns with memantine
• Access policies for generics and brand-to-generic conversion

For business planning, the practical question is: does ongoing evidence increase persistence and reduce discontinuation? In symptomatic AD drugs, small changes in adherence and discontinuation can move prescription share even without label changes.

---

Regulatory and Patent Reality That Drives the Market

Aricept (donepezil) is a legacy small molecule. Most large markets have moved through patent expiry and into generic competition. That sets expectations for:

• limited pricing power
• market share dependence on contracting
• revenue sensitivity to reimbursement rules and pharmacy switching

This environment explains why current “clinical trial updates” for donepezil are usually lifecycle rather than label-expanding.

---

Key Business Implications (What to Do With This Information)

1. Plan for generic erosion dynamics, not blockbuster growth. Aricept’s growth profile is structurally capped by mature patent status and generic penetration.
2. Treat real-world evidence and adherence/persistence as leading indicators. In symptomatic AD markets, those metrics drive share in payer-managed formularies.
3. Monitor adoption of disease-modifying therapies by payer segment. If eligibility expands, symptomatic-only demand may shift by stage and patient mix.
4. Expect regional variability. Pricing and access differ widely by geography and contracting sophistication.

---

Key Takeaways

• Aricept (donepezil) is a symptomatic Alzheimer’s therapy with mature clinical positioning and no current pattern of major late-stage registrational expansion driving label change.
• The market is dominated by persistent demand for symptomatic treatment, counterbalanced by generic pricing compression and competitive substitution.
• Market projection is primarily a function of treated AD population growth, net price decline from generic mix, and payer behavior shaped by disease-modifying therapy adoption.

---

FAQs

1) Is Aricept currently used to treat Alzheimer’s symptoms rather than slow disease progression?
Yes. Aricept is used for symptomatic management of Alzheimer’s disease dementia.

2) Does Aricept have new pivotal Phase 3 programs that can materially expand the label?
No consistent public indication supports a current registrational expansion pattern for new indications.

3) What drives Aricept revenue in mature markets?
Treated patient volume, prescription persistence, and payer contracting, offset by generic price pressure.

4) How does competition affect Aricept share?
Share depends on relative tolerability, guideline alignment, managed-care placement, and substitution among acetylcholinesterase inhibitors and memantine-based strategies.

5) What is the most important external market trend to watch for Aricept?
Disease-modifying therapy uptake and resulting shifts in patient mix and payer utilization of symptomatic-only regimens.

---

References

[1] U.S. Food and Drug Administration. Aricept (donepezil hydrochloride) prescribing information and regulatory materials. FDA label archive.
[2] National Institute on Aging (NIA), National Institutes of Health. Alzheimer’s disease overview and treatment discussion.
[3] Alzheimer’s Association. Alzheimer’s disease facts and figures (prevalence and projections).
[4] World Health Organization. Dementia and Alzheimer’s disease background resources.